Document is current

Any future updates will be listed below

1151 Preclinical development of CTX-10726, a tetravalent bispecific antibody targeting PD-1 and VEGF-A for the treatment of patients with cancer

Crossref DOI link: https://doi.org/10.1136/jitc-2025-SITC2025.1151

Published Online: 2025-11-04

Published Print: 2025-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark